Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 18/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769277 | 0.85 | PGR (0.67) | PGRARBACE1CHEK1NR3C1 | |
| SCHEMBL6769755 | 0.84 | PGR (0.66) | PGRARNR3C1 | |
| SCHEMBL6771936 | 0.80 | PGR (0.68) | PGR | |
| SCHEMBL6777083 | 0.80 | PGR (0.60) | PGR | |
| SCHEMBL3870851 | 0.77 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL14989874 | 0.77 | PGR (0.65) | PGRARNR3C1 | |
| SCHEMBL3518135 | 0.75 | PGR (1.00) | PGRARCHEK1 | |
| SCHEMBL4423015 | 0.74 | PGR (1.00) | PGRARBACE1CHEK1 | |
| SCHEMBL4104108 | 0.73 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL3872645 | 0.72 | PGR (1.00) | PGRARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693103-B2 | CONTRACEPTION, TREATMENT OF FIBROIDS, ANTICARCINOGENIC AND -TUMOR AGENTS (ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER), AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY; BENIGN PROSTATIC HYPERTROPHY; ADENOCARCINOMAS | WYETH | 2004-02-17 | — | — | US | claimed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | claimed |
| US-6693103-B2 | CONTRACEPTION, TREATMENT OF FIBROIDS, ANTICARCINOGENIC AND -TUMOR AGENTS (ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER), AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY; BENIGN PROSTATIC HYPERTROPHY; ADENOCARCINOMAS | WYETH | 2004-02-17 | — | — | US | disclosed |
| US-6498154-B1 | CONTRACEPTION; PROGESTATIONAL ACTIVE LEVONORGESTREL AND AN ANTIPROGESTIN COMPOUND | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1175404-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066560-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | PGR 1/4885AR 16/4885BACE1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.